Wave Life Sciences Ltd. (WVE)
NasdaqGM
Price as at 1 Oct 2026, 04:00 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Wave Life Sciences Ltd. trades at $3.70. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Wave Life Sciences Ltd.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its WVE data?
Fundamentals for WVE come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 04:00 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for WVE, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.